The global acne medication market reached a value of about USD 10.07 Billion in 2024, driven by the growing prevalence of acne disorders and the popularity of retinoids across the globe. The market is further expected to grow at a CAGR of 4.20% in the forecast period of 2025-2034 to attain nearly USD 15.20 Billion by 2034.
Base Year
Historical Year
Forecast Year
Companies are pursuing mergers and acquisitions to expand their acne medication portfolios, strengthening their presence and addressing diverse consumer needs in the global market.
Strategic partnerships are enabling firms to leverage advanced technologies, such as AI-driven dermatology platforms, to develop personalised and effective acne treatment solutions.
Increased investment in research and development is driving innovation, with companies launching novel drug formulations and over-the-counter products to capture emerging market opportunities.
Acne is a common skin condition caused by clogged hair follicles due to oil, dead skin cells, and bacteria. It often appears as pimples, blackheads, or cysts, primarily on the face, chest, and back. Treatment options include topical medications like benzoyl peroxide, salicylic acid, and retinoids to reduce inflammation and unclog pores. Oral treatments, including antibiotics, hormonal therapies, and isotretinoin, target severe or persistent cases. Over-the-counter products and prescription drugs are widely used, depending on acne severity, ensuring effective management and improved skin health.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Innovation and Research Advancements Boost Acne Medication Market Growth
The global market is experiencing growth driven by the increasing demand for advanced treatments and breakthroughs in research. For instance, in October 2024, AccureAcne, Inc. announced that the FDA had cleared its Accure Laser System for long-term treatment. This system, first approved in 2022, targets acne vulgaris with its unique 1726 nm laser wavelength, offering precise control over the thermal gradient to target sebaceous glands. The incorporation of forced air cooling and real-time monitoring sets it apart from traditional options. The impact of this approval will likely drive market growth as more effective and non-invasive treatments gain popularity in the forecast period.
Strategic Collaborations to Boost Acne Medication Market Demand
Strategic partnerships are set to drive significant innovation in the acne medication market. In November 2024, Sanofi, A*STAR, and the National Skin Centre Singapore formed a collaboration to advance acne treatment research. This partnership will focus on a Phase 1 clinical study targeting mild acne, set to begin in Q2 2025. The collaboration combines Sanofi’s expertise with clinical infrastructure in Singapore, aiming to identify key biological markers affecting acne severity. This partnership is expected to accelerate the development of new treatments, expanding the acne medication market with more effective solutions and further driving market growth during the forecast period.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Growing Demand for Personalised Acne Treatments
The market is witnessing increasing interest in personalised treatment options driven by advancements in genetic research and AI technologies. Dermatologists and pharmaceutical companies are leveraging patient-specific data to design customised therapies, including targeted medications and skincare regimens. This trend addresses diverse skin types and acne severities, enhancing treatment efficacy and reducing side effects. The rise of telemedicine platforms has further boosted accessibility to personalised care. With growing consumer awareness and demand for tailored solutions, this trend is expected to drive market growth in the coming years.
Rising Demand for Holistic and Science-Backed OTC Acne Treatments to Boost Acne Medication Market Value
The market is witnessing a shift towards holistic and integrative solutions, driven by increasing consumer preference for products that combine modern science with traditional practices. For instance, in July 2023, Codex Labs, a Silicon Valley-based bio-skintech company, launched the second and third products in its Shaant line of over-the-counter (OTC) acne topicals. The Shaant line reflects the growing trend of combining dermatological innovation with holistic wellness. Rooted in Ayurvedic principles, these products emphasise a comprehensive approach to skin health, addressing acne through nutrition, mental well-being, and lifestyle. This trend highlights a broader market evolution towards personalised, multi-faceted acne management solutions, meeting consumer demand for safe, effective, and natural treatment options.
Technological Advancements in Acne Treatment Devices to Enhance Acne Medication Market Size
The integration of technology in acne treatment is reshaping the market, with devices like blue light therapy and laser treatment systems gaining popularity. These non-invasive solutions offer faster results and are often used alongside traditional medications for comprehensive care. Innovations in wearable technology and AI-driven skincare diagnostics are further empowering consumers to monitor and manage acne effectively. Increasing adoption of such devices, supported by greater awareness of advanced treatments, is set to drive market development and strengthen the focus on technology-led skincare.
Expanding Use of Combination Therapies in Acne Management to Augment Acne Medication Market Growth
The market is witnessing a significant trend toward the development of innovative combination therapies that address multiple acne mechanisms simultaneously. These advanced treatments aim to enhance patient outcomes by offering more comprehensive and effective solutions. In a pivotal development in October 2023, Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics, announced FDA approval of CABTREO™ (clindamycin phosphate, adapalene, and benzoyl peroxide) topical gel. As the first and only fixed-dose, triple-combination topical treatment for acne vulgaris, CABTREO™ combines antibiotic, retinoid, and antibacterial agents in one formulation, providing a groundbreaking option for patients aged 12 and older. Expected to launch in Q1 2024, this innovation aligns with market demand for targeted, efficient therapies, reinforcing the focus on patient-centric acne solutions.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Therapeutic Class
Market Breakup by Formulation
Market Breakup by Type
Market Breakup by Acne Type
Market Breakup by Population Type
Market Breakup by Distribution Channel
Market Breakup by Region
Retinoids to Lead the Therapeutic Class Segment
Retinoids dominate the therapeutic class segment due to their proven efficacy in treating mild to severe acne by regulating skin cell turnover and preventing clogged pores. Their ability to reduce acne scars and improve skin texture makes them a preferred choice for dermatologists and consumers alike. Increasing R&D investments in innovative retinoid formulations and growing awareness of their benefits are driving market growth. This segment’s strong demand, bolstered by its versatility in combination therapies, positions retinoids as a significant driver of future growth in the acne medication market.
Topical Medications to Lead the Formulation Segment in the Acne Medication Market
Topical medications hold the largest market share due to their ease of application, affordability, and widespread availability. These formulations, including creams, gels, and lotions, are effective for mild to moderate acne cases, targeting specific areas without systemic side effects. Rising consumer preference for non-invasive solutions and the development of advanced topical products with enhanced penetration are driving their adoption. The continued innovation in formulation technologies ensures topical medications remain a cornerstone of acne treatment, supporting sustained market growth.
Acne Medication Market Segmentation by Type to Hold a Substantial Share
Over-the-counter (OTC) medications dominate the market by type, driven by their accessibility, cost-effectiveness, and increasing consumer inclination towards self-care. Products containing benzoyl peroxide, salicylic acid, and natural ingredients are highly sought after for managing mild acne. The growing awareness of skincare and preventive measures has amplified OTC product sales through retail and online channels. As companies invest in marketing and product development, OTC medications are poised to maintain their dominance, contributing significantly to market growth during the forecast period.
Inflammatory Acne to Dominate the Acne Medication Market Share by Acne Type
Inflammatory acne is expected to lead the share by acne type due to its prevalence and the complexity of treatment. This category includes papules, pustules, nodules, and cysts, often requiring comprehensive care with antibiotics, retinoids, and combination therapies. Increasing awareness of long-term treatment options and the rising demand for advanced formulations drive this segment’s growth. The focus on developing targeted therapies to minimise scarring and inflammation positions inflammatory acne treatment as a key market driver.
Offline Channels to Hold a Significant Value in the Acne Medication Market
Offline channels, particularly pharmacies and drug stores, dominate the distribution channel segment. These outlets provide trusted access to both prescription and OTC acne medications, supported by in-store guidance from healthcare professionals. The convenience of immediate availability and the growing footprint of retail chains bolster this segment’s leadership. While online channels are expanding rapidly, the offline segment continues to thrive due to consumer trust and accessibility, ensuring its significant contribution to the market’s value and development in the forecast period.
North America holds the largest market share in the acne medication industry, primarily due to its advanced healthcare infrastructure, high disposable income, and a strong focus on dermatological research. The prevalence of acne among adolescents and adults, coupled with increased skincare awareness, has driven demand for prescription and over-the-counter products. As per the analysis by Expert Market Research, the acne therapeutics market is expected to grow at a CAGR of 4.6% during the forecast period of 2024-2032. The region also benefits from the presence of leading pharmaceutical companies and ongoing advancements in acne treatments, such as combination therapies and personalised care. Robust investments in innovative formulations and strong adoption of technologically advanced treatment devices position North America as a key driver of market growth.
The key features of the market report comprise patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Founded in 1943 and headquartered in Barcelona, Spain, Almirall S.A. is a leading global biopharmaceutical company specialising in dermatology. The company’s portfolio includes innovative treatments for various skin conditions, including acne, psoriasis, and atopic dermatitis. Almirall has made significant strides in the global acne medication market through the development and commercialisation of effective therapies aimed at improving patient outcomes. For instance, in March 2024, Almirall entered an exclusive license agreement with Eloxx Pharmaceuticals to develop and commercialise ZKN-013, a promising oral drug targeting rare dermatological diseases. Although primarily focused on orphan conditions, this collaboration highlights Almirall’s commitment to advancing dermatological innovation, showcasing its expertise in addressing complex skin disorders and reinforcing its leadership position in the dermatology and acne treatment sectors globally.
Bausch Health Companies Inc., headquartered in Laval, Canada, was established in 1959 and is a leading global pharmaceutical company. The organisation specialises in developing, manufacturing, and marketing prescription drugs, over-the-counter products, and medical devices, with a strong focus on dermatology, gastroenterology, and eye health. In November 2024, its Canadian division announced that PrCABTREO™ gel, a triple-combination topical treatment for acne vulgaris, received positive reimbursement recommendations from Canada's Drug Agency and Quebec's INESSS. CABTREO™ is the first Health Canada-approved acne treatment combining an antibiotic, a retinoid, and an antibacterial agent. This milestone highlights Bausch Health's innovative portfolio in the acne medication market, offering advanced therapeutic solutions and reinforcing its position as a significant contributor to global dermatology advancements.
GlaxoSmithKline (GSK), headquartered in Brentford, UK, and established in 2000, is a global healthcare leader with a significant focus on dermatology. In the acne medication market, GSK provides effective therapies, including antibiotics and anti-inflammatory solutions designed to manage various forms of acne. With a strong emphasis on scientific innovation and a patient-first approach, GSK’s acne portfolio aligns with its mission to improve skin health. The company’s strategic collaborations and investments in dermatological research strengthen its position in the competitive acne treatment sector.
Johnson & Johnson Services, founded in 1886 and headquartered in New Brunswick, New Jersey, is a global leader in healthcare and consumer products. Its portfolio in the acne medication market includes well-known brands like Neutrogena, offering topical solutions, cleansers, and spot treatments. The company’s dermatological expertise extends to prescription-strength products targeting more severe acne conditions. Through innovation, consumer trust, and a comprehensive range of accessible treatments, Johnson & Johnson remains a dominant player in the acne care market globally.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Galderma S.A., Mayne Pharma Group Limited., AbbVie Inc., Teva Pharmaceutical Industries Ltd., and Botanix Pharmaceuticals.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Therapeutic Class |
|
| Breakup by Formulation |
|
| Breakup by Type |
|
| Breakup by Acne Type |
|
| Breakup by Population Type |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share